Current Report Filing (8-k)
August 23 2022 - 4:54PM
Edgar (US Regulatory)
0001415684
false
0001415684
2022-08-17
2022-08-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported): August 17, 2022
MusclePharm
Corporation
(Exact
Name of Registrant as Specified in Charter)
Nevada
(State
of Incorporation)
000-53166 |
|
77-0664193 |
(Commission
File Number) |
|
(I.R.S.
Employer Identification No.) |
6728
W. Sunset Rd., Ste. 130, Las Vegas, NV |
|
89118 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
(800)
859-3010 |
(Registrant’s
Telephone Number, Including Area Code) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities
registered pursuant to Section 12(b) of the Act
Title
of Each Class |
|
Trading
Symbol |
|
Name
of Each Exchange on Which Registered |
N/A |
|
N/A |
|
N/A |
Securities
registered pursuant to Section 12(g) of the Act: Common Stock, par value $0.001 per share
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
August 17, 2022, Eric Chin resigned as Chief Financial Officer, Chief Accounting Officer and Director of MusclePharm Corporation for
personal reasons.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
August
23, 2022 |
By:
|
/s/
Ryan Drexler
|
|
Name: |
Ryan
Drexler |
|
Title: |
Chief Executive Officer |
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Jul 2023 to Jul 2024